Drug Profile


Alternative Names: GHRP-2; GPA 748; Growth hormone releasing peptide 2; KP-102 D; KP-102 LN

Latest Information Update: 02 Jun 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Polygen; Tulane University
  • Developer Kaken Pharmaceutical; Wyeth
  • Class Peptide diagnostics
  • Mechanism of Action Ghrelin receptor agonists; Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Somatotropin deficiency
  • Discontinued Short stature

Most Recent Events

  • 16 Oct 2009 Wyeth has been acquired by Pfizer
  • 12 Sep 2007 Pralmorelin is still in phase II trials for Short Stature in Japan
  • 14 Mar 2005 Launched for Somatropin deficiency (diagnosis) in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top